Sign in

Joshua Thomas Jennings

Research Analyst at Cowen Inc.

Joshua Thomas Jennings, MD, is Managing Director and Senior Healthcare Analyst at TD Cowen, specializing in coverage of leading medical technology companies such as Insulet (PODD), Butterfly Network (BFLY), and TransMedics (TMDX). Renowned for his analytical rigor, Jennings boasts notable performance metrics: a TipRanks success rate around 47%, an average return between 0.8% and 5.2%, and top individual trade returns exceeding 380%. Jennings started his analyst career at Jefferies & Company, later joining Cowen and Company in 2011—now TD Cowen—where he rose to Managing Director. He holds FINRA registration (CRD# 5275612) and is licensed as a broker with TD Securities (USA) LLC, with additional credentials as an MD.

Joshua Thomas Jennings's questions to ABBOTT LABORATORIES (ABT) leadership

Question · Q3 2025

Joshua Thomas Jennings asked for details on the drivers of double-digit ablation catheter growth in the EP franchise, the expected performance of the mapping franchise in 2026 given competitive evolution, and projected CPFA penetration rates in the U.S. and OUS by the time Volt launches globally in 2026.

Answer

Chairman and CEO Robert Ford attributed double-digit ablation catheter growth primarily to international markets and a full portfolio including diagnostics and new products like the 13 French Agilisheath and ICE. He affirmed Abbott's leadership in mapping cases despite new competitors. He agreed that CPFA penetration could reach over 80% in the U.S. by 2026, with international markets potentially mimicking this high rate due to Volt.

Ask follow-up questions

Get Instant Answers from SEC Filings & Earnings Calls

Ask complex financial questions and get precise answers in seconds. Fintool scans millions of documents to surface insights beyond timely human analysis.

Search across 8,000+ companies
Access millions of SEC filings & transcripts
Get answers cited to the source
Try Fintool for Free

Trusted by leading investment firms and analysts